We investigated the effects of enalapril therapy on plasma tissue factor (TF), tissue factor pathway inhibitor (TFPI) and monocyte chemoattractant protein-1 (MCP-1) levels in patients with acute myocardial infarction.
Data from large placebo-controlled studies have indicated that the administration of angiotensin-converting enzyme (ACE) inhibitors in patients with myocardial infarction is associated with an improvement in survival (1) (2) (3) . Tissue factor (TF) is a low molecular weight glycoprotein that binds and acts on essential cofactor factor VII, and the resulting complex activates factor IX and X, and initiates the clotting cascade in vivo (4 -6) . There has been a report that hypercoagulability in patients with acute coronary syndromes is associated with TF induced on circulating monocytes (7) . We have also demonstrated that plasma TF levels are elevated in patients with myocardial infarction and unstable angina (8 -10) . Annex et al. (11) reported that TF protein was expressed in directional atherectomy specimens from patients with acute coronary syndromes.
Furthermore, we have also shown that the expression of TF on macrophages is more frequent in the coronary atherosclerotic plaques in patients with unstable angina than in those with stable exertional angina, and fibrin deposition is mainly observed around massive infiltration of the TFpositive macrophages in patients with unstable angina (12) . Recent data have shown that the instability of the atherosclerotic plaque is closely related to its macrophage content (13) . Monocyte chemoattractant protein-1 (MCP-1) has a potent chemotactic activity for monocytes (14) and activates monocytes (15) . We reported the elevation of plasma MCP-1 levels in patients with acute coronary syndromes (16) .
In contrast, tissue factor pathway inhibitor (TFPI) regulates the initial step of the extrinsic coagulation pathway mediated by TF (17) . Sandset et al. (18) demonstrated that the TFPI level increases in patients with acute coronary disease. We also showed that plasma levels of TFPI increased in the coronary circulation after coronary spasm (19) . We investigated whether the administration of ACE inhibitor might modify plasma TF, free TFPI and MCP-1 levels in patients with myocardial infarction.
METHODS
Subjects. This study was designed as a randomized, double-blind, placebo-controlled study. Entry into the study was two weeks after the onset of myocardial infarction to avoid any acute-phase response. Thirty-two patients with their first myocardial infarction were recruited two weeks after admission to the hospital. All patients were diagnosed as having acute myocardial infarction based on typical chest pain lasting Ͼ30 min with ST-segment elevation of Ͼ0.2 mV in Ͼ2 continuous leads on a standard 12-lead electrocardiogram (ECG) and an increase of creatine kinase level at least twice the upper level of normal. No patients had previously taken an ACE inhibitor. Patients took betaadrenergic blocking agents, calcium antagonists, long-acting nitrates and aspirin daily from the time of admission. In addition, patients started to receive a placebo or 5 mg of enalapril each morning for four weeks. No patients had a significant hypotensive response or abnormal electrolytes during this study. Informed consent was obtained from each patient.
Sampling. Blood samplings were performed on the day before the administration, and on days 3, 7 and 28 after the start of enalapril or placebo administration. All patients were supine, and a 21-gauge needle was inserted into a large antecubital vein. An initial 3 ml of blood was used for measuring lipid concentrations; an additional 4.5 ml of blood for TF, free TFPI and MCP-1 assay was drawn into a tube containing sodium citrate (0.13 mol/liter, pH 7.5). Subsequently, 5 ml of blood for measurement of ACE activity was drawn into a plain glass tube. The samples for TF, free TFPI and MCP-1 assay were immediately centrifuged at 3000 rpm for 10 min at 4°C. The samples for lipid concentrations and ACE activity assay were left in room air for 30 min and centrifuged in the same way. After centrifugation, the samples were immediately stored at Ϫ80°C until analysis.
Assays. Serum ACE activity was measured by the ACE color method (Fujirevio, Tokyo). We previously reported using this kit (10). The normal value of ACE activity in our laboratory (n ϭ 16) is 14.8 Ϯ 3.9 (mean Ϯ SD) IU/liter.
Plasma TF antigen levels were measured by the enzymelinked immunosorbent assay (ELISA) kit (TF ELISA Kit "KAKETSUKEN") purchased from Sanko Junyaku (Tokyo). We previously reported using this kit (9). The normal TF value in our laboratory (n ϭ 16) is 172 Ϯ 32 (mean Ϯ SD) pg/ml.
Plasma free TFPI antigen levels were measured by the ELISA kit (Free TFPI ELISA Kit "KAKETSUKEN") purchased from Sanko Junyaku . We previously reported using this kit (16) . The normal free TFPI value in our laboratory (n ϭ 16) is 24.1 Ϯ 6.5 (mean Ϯ SD) ng/ml.
Plasma MCP-1 level was measured using a recently described Hbt Human MCP-1 ELISA Kit developed by Hycult Biotechnology B.V. (Uden, The Netherlands). We previously reported using this Kit (19) . The normal MCP-1 value in our laboratory (n ϭ 16) is 531 Ϯ 99 (mean Ϯ SD) pg/ml.
Statistical analyses.
All data are shown as mean value Ϯ SD. The clinical characteristics of the two patient groups with myocardial infarction were compared using an unpaired t test for continuous data and chi-square test for frequency data. Plasma TF, free TFPI and MCP-1 levels and serum ACE activity between the enalapril and placebo group before administration were compared using the Mann-Whitney U test. Those levels between the normal group and patient group were also compared using the Mann-Whitney U test. The plasma TF, free TFPI and MCP-1 levels and serum ACE activity levels over the time course in the two patient groups were, respectively, compared by two-way analysis of variance (ANOVA) for repeated measures that included treatment and stratum as main effects and treatment-by-stratum interactions. When the results were significant, the significance level for correlations is given after applying the Bonferroni method (20) . A linear regression analysis was used to determine the correlations between the two variables. Probability levels less than 0.05 were considered significant.
RESULTS
Baseline characteristics. The clinical characteristics of patients are listed in Table 1 . There were no significant differences in frequencies of hypertension, obesity, diabetes mellitus and history of smoking, and in the levels of serum total cholesterol, triglyceride and high-density lipoprotein (HDL) cholesterol between the enalapril and placebo groups. There were also no significant differences in medi- The three variables after administration. The following were p values of the main effects and the interaction resulting from two-way repeated measures ANOVA. The main effect was p Ͻ 0.001 and interaction was p Ͻ 0.001 in the ACE activity; main effect was p ϭ 0.036 and interaction was p ϭ 0.005 in the TF levels; main effect was p Ͻ 0.001 and interaction was p ϭ 0.020 in the MCP-1 levels; and main effect was p ϭ 0.725 and interaction was p ϭ 0.993 in the free TFPI levels. The ACE activity (IU/liter) in the enalapril group significantly decreased from 14.0 Ϯ 5.7 before the administration to 5.2 Ϯ 3.5 on day 3 (Fig. 1) . The activity on days 7 and 28 was also significantly lower. The ACE activity in the placebo group did not significantly change during the study period. Activity on days 3, 7 and 28 in the enalapril group was significantly lower than that in the placebo group.
The TF levels (pg/ml) in the enalapril group significantly decreased from 223 Ϯ 58 before administration to 182 Ϯ 39 on day 7 (Fig. 2) . The levels on day 28 were also significantly lower. The TF levels in the placebo group did not significantly change during the study period. The levels on days 7 and 28 in the enalapril group were significantly lower than those in the placebo group.
The free TFPI levels in either the enalapril or placebo group did not significantly change during the study period (Fig. 3) . The MCP-1 levels (pg/ml) in the enalapril group significantly decreased from 919 Ϯ 173 before the administration to 789 Ϯ 128 on day 3 (Fig. 4) . The levels on days 7 and 28 were also significantly lower. The MCP-1 levels in the placebo group did not significantly change during the study period. The MCP-1 levels on days 3, 7 and 28 in the enalapril group were significantly lower than those in the placebo group.
The correlation between two variables. The correlation coefficient among the ACE activity, TF, free TFPI and MCP-1 levels before the administration was calculated in all patients. There was a good correlation (r ϭ 0.734, p Ͻ 0.0001) between the ACE activity and the MCP-1 levels (Fig. 5A ). The ACE activity was positively correlated with the TF levels (r ϭ 0.553, p ϭ 0.0010, Fig. 5B ). Furthermore, MCP-1 levels were also positively correlated with TF levels (r ϭ 0.746, p Ͻ 0.0001, Fig. 5C ). There were no correlations between the free TFPI levels and the other variables.
DISCUSSION
The use of ACE inhibitors in patients with myocardial infarction is known to reduce the morbidity and mortality by major cardiovascular events (1- 
recently demonstrated that administration of ACE inhibitor decreases plasma PAI-1 levels in patients with myocardial infarction. We also showed the effects of ACE inhibitor on endogenous fibrinolysis in patients with recent myocardial infarction (22) . In contrast, we have demonstrated that plasma TF levels are elevated in patients with myocardial infarction and unstable angina in the previous studies (8 -10) . These results show that there is an abnormal activation of the procoagulant system in patients with myocardial infarction. Recently, it was revealed that plaques from patients with unstable angina or myocardial infarction had significantly high concentrations of TF antigen and activity, and that heightened TF levels contribute to the high procoagulant activity of atherosclerotic lesions in the coronary artery (23) (24) (25) . The plasma TF levels decreased after administration of enalapril in the present study. This fact is consistent with the data that exposure of vascular smooth muscle cells and aortic endothelial cells to angiotensin II induced expression of TF mRNA (26, 27) .
In the present study, plasma TF levels decreased along with ACE activity, and there was a positive correlation between the TF levels and the ACE activity. These data may indicate that the inhibition of ACE decreases the over-expression of TF in patients with myocardial infarction. In plasma there are two types of TF: One is a membrane-bound form with potent procoagulant activity, and the other is a soluble form with a faint procoagulant activity. We reported that there is good correlation between procoagulant activity and plasma membrane-bound TF levels in patients without renal dysfunction.
Furthermore, we observed a highly positive correlation between plasma TF levels and membrane-bound TF levels in another study on myocardial infarction without renal dysfunction (28) . None of the patients in the present study had renal dysfunction. Therefore, in the current study it is suggested that the elevation of plasma TF level reflects the heightened TF activity-that is, heightened procoagulant activity-and that it also reflects the increase of membranebound TF from atherosclerotic lesions of myocardial infarction.
Most TFPI is synthesized in endothelial cells (29, 30) and binds with proteoglycans on the endothelial cell surface (31) (32) (33) . The TFPI can be separated into free TFPI, lipoprotein-associated TFPI and endothelial cell-associated TFPI. Total TFPI consists of free TFPI and lipoproteinassociated TFPI. It is reported that anticoagulant activity of lipoprotein-associated TFPI is markedly lower than that of free TFPI (34) and that free TFPI reflects the changes in endothelial cell-associated TFPI (35) . In the present study, the free TFPI levels did not change after administration of enalapril, and the levels were not correlated with the ACE activity or TF levels. These data are supported by the report that exposure of aortic endothelial cells to angiotensin II did not affect the expression of TFPI mRNA (27) .
Recently, it has been reported that the presence of TFPI in human atherosclerotic plaques is associated with reduced TF activity (36) . The present study showed that not only the plasma TF levels but also the free TFPI levels were examined after administration of enalapril. It was also reported that administration of recombinant TFPI attenuates stenosis after balloon-induced arterial injury (37). Falciani et al. (38) concluded that blood clotting activation observed in patients with ischemic heart disease was related to elevated TF circulating levels not sufficiently inhibited by the elevated TFPI levels present. It may be an important finding that administration of enalapril diminished TF levels but did not affect TFPI levels.
Monocyte chemoattractant protein-1 is expressed by vascular smooth muscle cells, endothelial cells and monocytes (39 -41) . In the present study, plasma MCP-1 levels were higher in the patients with myocardial infarction than in normal patients, and were positively correlated with plasma TF levels. Furthermore, plasma TF level decreased along with a decrease in MCP-1 level. These results are inferred by the report that MCP-1 induces the expression of TF in human monocytes (42) . Matsumori et al. (43) recently reported that plasma MCP-1 levels are elevated in patients with acute myocardial infarction. Hernàndez-Presa et al. (44) have recently shown that angiotensin II increases 
